Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.60 |
| ▸ | MMP13 | P45452 | 16/20 | 0.60 |
| ▸ | MMP2 | P08253 | 3/20 | 0.54 |
| ▸ | MMP3 | P08254 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | MMP14 | P50281 | 2/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.48 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056867 | 0.89 | MMP1 (0.60) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL27415619 | 0.87 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6869740 | 0.85 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL5914587 | 0.82 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL2575324 | 0.81 | MMP1 (0.79) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL16013385 | 0.79 | MMP1 (0.62) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL27448685 | 0.79 | MMP1 (0.64) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7886290 | 0.78 | MMP1 (0.62) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL5139159 | 0.78 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208011 | 0.77 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148839-A1 | New pharmaceutical compositions based on anticholinergics and tace-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | claimed |
| EP-1622617-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND TACE-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-08 | — | — | EP | claimed |
| WO-2004071384-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND TACE-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-0977733-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | ROBINSON RALPH PELTON (US) | 2002-01-17 | — | — | US | claimed |
| US-6303636-B1 | FOR THERAPY OF ARTHRITIS, CANCER, TISSUE ULCERATION, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCIERITIS, SEPSIS, SEPTIC SHOCK AND OTHER DISEASES INVOLVING THE PRODUCTION OF TUMOR NECROSIS FACTOR | PFIZER INC | 2001-10-16 | — | — | US | claimed |
| EP-0977733-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | claimed |
| US-20060148839-A1 | New pharmaceutical compositions based on anticholinergics and tace-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1622617-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND TACE-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004071384-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND TACE-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| EP-0977733-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | ROBINSON RALPH PELTON (US) | 2002-01-17 | — | — | US | disclosed |
| EP-0977733-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | MMP8, MMP1, MMP10 | MMP1 2/4885MMP13 18/4885MMP2 6/4885 |
| US-20060148839-A1 | New pharmaceutical compositions based on anticholinergics and tace-inhibitors | TPSAB1, CMA1, TPSG1 | MMP1 700/4885MMP13 886/4885MMP2 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.